Hey,
Twenty-four issues in, I did a quick tally of what we've covered together: cold plunges, mouth tape, red light panels, seed oils, 10,000 steps, sleeping positions, whether you can drink water with a meal. That's before we even get to the peptides.
I love this stuff. That's why this newsletter exists. But lately I've been grappling with a question that I think anyone who spends time in this world eventually has to ask: at what point does health optimization stop making you healthier?
You've probably seen the version I mean. It's the person who has decided there are only a handful of foods they're allowed to eat. It's the person whose every meal, workout, and bedtime is a lever being pulled to add a few more months of healthspan, to the point where the managing of their life starts to crowd out the living of it. The goal was supposed to be feeling good and doing more of what you love. Somewhere along the way the optimizing became the thing itself.
I myself am not above this. I read trial data for fun. But when I started this newsletter, the whole idea was that it would be a fun, curious, informational journey that I got to take alongside all of you. Not a list of things to be anxious about. Not another set of rules. Just: here's what the research actually says, here's how confident we can be, now go live your life.
So consider this issue a small recalibration, and a deliberately fitting one. The lead compound is one of the most popular peptides for people who aren't sick but want to be "more." And the supplement in Claim vs Reality is one a lot of healthy people take just in case. Both raise the same question: what problem are we actually solving?
Let's get into it.
🔬 The Lead: Ipamorelin, and the Healthy Body Problem
If you've spent any time in peptide forums, you've seen Ipamorelin. Usually it's paired with CJC-1295, and usually it's described with one word: clean.
What it is. Ipamorelin is a synthetic pentapeptide, a chain of five amino acids, developed by Novo Nordisk in the 1990s. It works by mimicking ghrelin, binding the ghrelin receptor in the pituitary gland and triggering a pulse of growth hormone. When Novo's scientists first described it in 1998, they called it the first selective growth hormone secretagogue. Older compounds in its class, like GHRP-6, raised GH but dragged along hunger, cortisol, and prolactin. In the early animal work, ipamorelin raised GH without most of that baggage.
That selectivity is the entire reputation. It is why ipamorelin gets called "gentle," and why it shows up in so many longevity and performance routines.
What's actually been tested in humans. This is where the story gets thin fast.
Small pharmacology studies. Early human work, including a small dose-escalation study in healthy young men, confirmed that ipamorelin raises growth hormone and characterized how the body clears it. That tells you the molecule does what it was designed to do at the receptor. It tells you nothing about outcomes.
One real efficacy trial, and it failed. Ipamorelin's only completed, peer-reviewed randomized trial wasn't about muscle, fat, sleep, or aging at all. It tested whether IV Ipamorelin could speed gut recovery after bowel surgery, a condition called postoperative ileus. The trial enrolled 117 patients. Median time to first tolerated meal was 25.3 hours on ipamorelin versus 32.6 hours on placebo, a difference that was not statistically significant (p = 0.15). Development stopped there.
Nothing for what it's sold for. There are no published human trials of Ipamorelin for body composition, recovery, sleep quality, or anti-aging. The popular CJC-1295 plus Ipamorelin pairing has never been tested as a combination in a controlled trial either.
The regulatory record. In October 2024, the FDA's compounding advisory committee reviewed Ipamorelin, evaluated for growth hormone deficiency and postoperative ileus, after FDA reviewers concluded the evidence weighed against adding it to the list of substances pharmacies can compound. The committee voted 0 in favor, 12 against, with 1 abstention. Ipamorelin was not among the peptides the same committee backed this July, it isn't on the February 2027 docket, and Ipamorelin products were named in the FDA's August warning letters to online sellers. Whatever happens with the interim access policy, Ipamorelin is not part of that conversation.
The bigger question: should a healthy GH axis be pushed higher? Here's where Ipamorelin becomes a perfect case study for this issue's theme. Growth hormone and its downstream partner, IGF-1, naturally decline with age. The optimization pitch treats that decline as a problem to fix. The research is far less sure it's a problem at all.
The U-shaped curve. A UK Biobank analysis of about 381,000 adults found a U-shaped relationship between IGF-1 and death. People in the lowest tenth of IGF-1 had about 39% higher all-cause mortality than those in the middle, but people in the highest tenth also had about 17% higher mortality. Higher was not better. The middle was.
Age flips the sign. A second UK Biobank study of about 440,000 people found that high IGF-1 looked protective in younger adults but was linked to more disease and death in older adults. The researchers' own read was that older adults may actually benefit from dialing growth pathways down, not up. That's the exact population most interested in pushing GH higher.
The Ecuador cohort. Researchers followed about 100 people in Ecuador with Laron syndrome, a genetic condition where the body can't respond to growth hormone, for 22 years. None developed diabetes and only one had cancer, versus 5% and 17% of their roughly 1,600 relatives. They didn't live longer overall, but the two biggest diseases of aging largely skipped them.
None of this proves Ipamorelin is harmful. These are observational and genetic studies, not Ipamorelin trials, and low IGF-1 carries its own risks. Growth hormone deficiency is a real medical condition where replacement genuinely helps. The point is narrower: "more growth hormone" is not a straight line to "more healthspan," and the version of the claim that matters here, a healthy adult raising their GH for years, has never actually been tested.
The honest summary. Ipamorelin is a well designed molecule that does exactly what it was engineered to do at the pituitary. That's a mechanism claim, and it accurate. Every claim beyond that, leaner, stronger, better sleep, slower aging, rests on animal work, anecdote, and an assumption that a healthy body's GH level is a deficiency waiting to be corrected. The one time it went into a real efficacy trial, it missed. And the broader science on the GH-IGF-1 axis suggests the assumption itself might point the wrong way, especially as we get older.
RQS: 35/100 (Weak Evidence)
The RQS measures the quality of clinical research behind a compound. It is not a verdict on whether a compound is safe or whether it works. Ipamorelin carries our Animal Only note: the score reflects the human evidence, and the animal evidence is stronger than the total suggests.
⚖️Claim vs. Reality: "Everyone Should Be Taking CoQ10"
The claim: CoQ10 powers your mitochondria. Your levels drop as you age and drop further if you take a statin. So whether you're 30 or 70, healthy or not, a daily CoQ10 is cheap insurance for your heart, your energy, and your muscles.
The reality: The biology is real. The case for a healthy person taking it mostly isn't.
The biology part is true. Coenzyme Q10 is a molecule your body makes on its own. It shuttles electrons in the energy-producing machinery of your cells and acts as an antioxidant. And statins lower it, because they block the same production pathway the body uses to make both cholesterol and CoQ10. That's where the logic for supplementing came from, and it's a reasonable hypothesis. The question is whether it holds up when tested.
For healthy people, the effect is small to nonexistent. A meta-analysis published in the British Journal of Nutrition last December pooled 24 randomized trials in healthy adults. CoQ10 reliably raised blood levels. That part works. But the effect on exercise performance was small and inconsistent, partly disappeared once outlier studies were removed, and the authors rated their certainty as very low to low. Raising a number in your blood is not the same as changing anything you'd feel.
For statin muscle aches, the most common reason people take it, the evidence leans no. This is the use case most people have heard about, and it has been studied repeatedly. A 2020 meta-analysis of seven randomized trials found no improvement in statin-associated muscle pain versus placebo, and no improvement in people staying on their statin. An earlier meta-analysis in Mayo Clinic Proceedings reached the same conclusion, and so did a 2022 analysis. One 2018 meta-analysis did find a benefit, so the picture isn't perfectly clean, but the UK's NHS specialist pharmacy guidance and the European Atherosclerosis Society both advise against recommending it for this purpose.
Where the claim has a real kernel. It's in specific, sick populations, not healthy ones.
Heart failure. The Q-SYMBIO trial randomized 420 people with moderate to severe heart failure to CoQ10 or placebo for two years, on top of standard treatment. Cardiovascular death was 9% in the CoQ10 group versus 16% on placebo. That's a striking result. It's also one moderately sized trial, funded by CoQ10 manufacturers, that hasn't been confirmed by a large independent trial in the decade since. Long-time readers will recognize that as exactly what the Funding Independence and Replication dimensions of the RQS exist to flag.
Older adults low in selenium. A Swedish trial in elderly people with low selenium status reported fewer cardiovascular deaths with a combined selenium and CoQ10 supplement. That's a combination product, in a population with a specific deficiency. It doesn't tell you what CoQ10 alone does for a healthy 35-year-old.
The honest version of the claim: CoQ10 is a real molecule with a real job, and there are signals worth taking seriously in specific medical contexts, mostly heart failure, where it belongs in a conversation with a cardiologist. For a healthy person, there's no good evidence it improves energy, performance, or long-term outcomes. If you're on a statin and having muscle aches, the research says the better conversation is with your prescriber about the statin, not about adding a supplement. And CoQ10 isn't totally inert: it can interact with blood thinners like warfarin, which is one more reason "can't hurt, might help" isn't quite the right frame.
It's the same lesson as the lead, from the opposite direction. Ipamorelin pushes a healthy hormone higher. CoQ10 tops up a healthy molecule just in case. In both, the question worth asking first isn't "does this do something?" It's "do I have the problem this solves?"
📊 Research Quality Score: Spotlight
Here's a comparison from inside the catalog that I think gets at something the RQS can't tell you, and is worth mentioning.
Look at the growth hormone family:
Compound | RQS | Band | What the strong evidence is actually about |
|---|---|---|---|
HGH | 90 | Strong | Replacing GH in people who are deficient |
Tesamorelin | 88 | Strong | Reducing abdominal fat in people with HIV |
Sermorelin | 64 | Moderate | GH stimulation, mostly in GH deficiency |
Ipamorelin | 35 | Weak | Mechanism only; one failed surgical trial |
Two compounds in the same family score in the Strong band. It would be easy to read that as "the GH axis is well studied, so pushing it is evidence based." But look at the right-hand column. HGH's score is built on decades of trials in people whose bodies don't make enough growth hormone. Tesamorelin's is built on Phase 3 trials in a specific condition. Neither is a trial in healthy adults trying to feel younger.
That's the discipline this week. The RQS asks how strong the research is. But research is always research on someone, for something. A Strong score for treating a deficiency says nothing about what happens when a person without that deficiency takes the same compound. That isn't a flaw in the score. It's a reminder to read every score alongside the question of whether the people in the trials look like you.
As always: the RQS is not a safety rating, not an efficacy rating, and says nothing about what's in any vendor's vial.
📡 On My Radar
The interim peptide policy is picking up guardrails, and opponents. Quick follow-up to last issue. Bloomberg reported on October 22 that the plan under White House review includes more patient protections than expected, including a requirement for compounders to report side effects (Bloomberg). Secretary Kennedy said this week the goal is a state regulated marketplace for these peptides through 503A pharmacies. Meanwhile, the Partnership for Safe Medicines filed a citizen petition asking the FDA to stop compounding of these peptides, arguing it's both illegal and unsafe (RAPS), and pharma trade groups have already previewed a possible legal challenge (Holland & Knight). The text still isn't public. If adverse event reporting makes it into the final version, that's meaningful: it would create the first systematic safety data on these compounds in the U.S.
Another melanotan-II melanoma case, and a callback to Issue #11. Back in Issue #11 we covered melanotan-II, the tanning peptide whose development was abandoned while its cousin became an approved drug. This month, doctors in Michigan and Illinois published a case report of a man who developed a melanoma lesion after just five weeks of injecting melanotan-II he got through his gym. The doctors can't prove the drug caused it, and a single case report never can, but it adds to a growing pile of similar reports (Partnership for Safe Medicines summary). It's also a good illustration of item #1: right now, signals like this surface one case report at a time.
The retatrutide gray market is getting more attention, and more lawsuits. Since we checked retatrutide's Phase 3 data in Issue #22, a JAMA article has highlighted the growing black market for it, describing reports linking products labeled as retatrutide to hospitalizations and liver toxicity, plus lab tests finding wrong doses or entirely different ingredients (JAMA). Lilly has also filed five more lawsuits against online sellers, on top of the six from August (Bloomberg Law). The trial results are real. The vial bought online is not the trial drug.
🔍 From The Catalog: Creatine
To close an issue about not overdoing it, I want to spotlight the least exciting compound in the catalog. It also happens to be one of the best studied.
Creatine is a molecule your body makes from three amino acids, and it also comes from red meat and fish. It's stored mostly in muscle, where it helps regenerate energy during short, intense efforts like a heavy set or a sprint. It's been studied in hundreds of trials over decades, across many populations, by many independent research groups. Its evidence base is about as close to the opposite of Ipamorelin's as this catalog gets.
But here's why it belongs in this issue specifically. Creatine's strong evidence is for a specific job: more strength and power, mostly when paired with resistance training. Even the best evidenced supplement in the catalog is evidence for a particular goal, not a reason everyone needs it. If you lift and want to get stronger, the research is about as solid as supplement research gets. If you don't, there's no obligation to add it to your routine. There's also emerging research on cognition and aging that's pretty interesting but still earlier stage than the strength data.
There's something reassuring in that. The best supported item in the whole catalog is cheap, boring, decades old, and optional. Real evidence rarely looks like a secret.
RQS: 93/100 (Strong Evidence)
Hopefully that was helpful/interesting, see you next week.
-Emeka
You're receiving this because you signed up at peptideclear.com. No sponsors. No affiliate links. Just the research, translated.
